DT2216 in Combination with Irinotecan: A Phase 1 Study with a Phase 2 Feasibility Cohort for Fibrolamellar Carcinoma
Timeframe: 2025 – 2028 Goal: Provide the drug necessary to enable a FLC clinical trial Grantee: Dialectic Therapeutics, Inc. Principal Investigators of related clinical study: Dr. Allison O’Neill, Dana-Farber Cancer Institute and Dr. Michael Ortiz, Memorial Sloan Kettering Cancer Center Effort overview: This grant funds the manufacturing and distribution of an experimental drug, DT2216, for …